| Schedule of antidilutive shares |
| |
|
December 31, |
|
| |
|
2019 |
|
|
2018 |
|
| Restricted stock units |
|
|
2,000 |
|
|
|
4,000 |
|
| Options to purchase common stock |
|
|
358,000 |
|
|
|
160,000 |
|
| Warrants to purchase common stock |
|
|
468,000 |
|
|
|
468,000 |
|
| Series C |
|
|
17,000 |
|
|
|
17,000 |
|
| Common Stock Units (1) |
|
|
46,000 |
|
|
|
46,000 |
|
| |
|
|
891,000 |
|
|
|
695,000 |
|
______________
| (1) |
Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock |
|
| Disaggregated Revenue by Source |
| |
|
Three Months Ended December 31,
|
|
|
Nine Months Ended December 31,
|
|
| |
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
| Product |
|
|
|
|
|
|
|
|
|
|
|
|
| Human Skin Care |
|
$ |
3,528,000 |
|
|
$ |
4,497,000 |
|
|
$ |
11,290,000 |
|
|
$ |
12,125,000 |
|
| Animal Skin Care |
|
|
853,000 |
|
|
|
548,000 |
|
|
|
2,188,000 |
|
|
|
1,650,000 |
|
| |
|
|
4,381,000 |
|
|
|
5,045,000 |
|
|
|
13,478,000 |
|
|
|
13,775,000 |
|
| Service |
|
|
297,000 |
|
|
|
235,000 |
|
|
|
879,000 |
|
|
|
813,000 |
|
| Total |
|
$ |
4,678,000 |
|
|
$ |
5,280,000 |
|
|
$ |
14,357,000 |
|
|
$ |
14,588,000 |
|
|